Eulalia Grau
Overview
Explore the profile of Eulalia Grau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
289
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gonzalez-Navarro I, Urrea V, Galvez C, Garcia-Guerrero M, Moron-Lopez S, Puertas M, et al.
J Clin Invest
. 2024 Nov;
135(2.
PMID: 39610346
BACKGROUNDAntiretroviral therapy (ART) has improved the clinical management of HIV-1 infection. However, little is known about how the latest ART recommendations affect the heterogeneity of the HIV-1 reservoir size.METHODSWe used...
2.
Llados G, Massanella M, Coll-Fernandez R, Rodriguez R, Hernandez E, Lucente G, et al.
Clin Microbiol Infect
. 2023 Nov;
30(4):515-521.
PMID: 37984511
Objectives: The post-COVID-19 condition (PCC) is a disabling syndrome affecting at least 5%-10% of subjects who survive COVID-19. SARS-CoV-2 mediated vagus nerve dysfunction could explain some PCC symptoms, such as...
3.
Pradenas E, Marfil S, Urrea V, Trigueros M, Pidkova T, Pons-Grifols A, et al.
iScience
. 2023 Mar;
26(4):106457.
PMID: 36999095
The elicitation of cross-variant neutralizing antibodies against SARS-CoV-2 represents a major goal for current COVID-19 vaccine strategies. Additionally, natural infection may also contribute to broaden neutralizing responses. To assess the...
4.
Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study
Abella E, Trigueros M, Pradenas E, Munoz-Lopez F, Garcia-Pallarols F, Ben Azaiz Ben Lahsen R, et al.
Life Sci Alliance
. 2022 Aug;
5(12).
PMID: 35961779
SARS-CoV-2 vaccination is the most effective strategy to protect individuals with haematologic malignancies against severe COVID-19, while eliciting limited vaccine responses. We characterized the humoral responses following 3 mo after...
5.
Trigueros M, Pradenas E, Palacin D, Munoz-Lopez F, Avila-Nieto C, Trinite B, et al.
Age Ageing
. 2022 May;
51(5).
PMID: 35595256
Background: SARS-CoV-2 vaccination is the most effective strategy to protect older residents of long-term care facilities (LTCF) against severe COVID-19, but primary vaccine responses are less effective in older adults....
6.
Hussain R, Ongaro A, Rodriguez de la Concepcion M, Wajs E, Riveira-Munoz E, Ballana E, et al.
Biomed Opt Express
. 2022 Apr;
13(3):1609-1619.
PMID: 35415002
Current diagnostics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection heavily rely on reverse transcription-polymerase chain reaction (RT-PCR) or on rapid antigen detection tests. The former suffers from long...
7.
Trinite B, Pradenas E, Marfil S, Rovirosa C, Urrea V, Tarres-Freixas F, et al.
Viruses
. 2021 Jul;
13(6).
PMID: 34204754
With the spread of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a need to assess the protection conferred by both previous infections and current vaccination....
8.
Trinite B, Tarres-Freixas F, Rodon J, Pradenas E, Urrea V, Marfil S, et al.
Sci Rep
. 2021 Jan;
11(1):2608.
PMID: 33510275
The protective effect of neutralizing antibodies in SARS-CoV-2 infected individuals is not yet well defined. To address this issue, we have analyzed the kinetics of neutralizing antibody responses and their...
9.
Gonzalez N, McKee K, Lynch R, Georgiev I, Jimenez L, Grau E, et al.
PLoS One
. 2018 Mar;
13(3):e0193773.
PMID: 29558468
Background: Only a small fraction of HIV-1-infected patients develop broadly neutralizing antibodies (bNAbs), a process generally associated to chronic antigen stimulation. It has been described that rare aviremic HIV-1-infected patients...
10.
Leon A, Perez I, Ruiz-Mateos E, Benito J, Leal M, Lopez-Galindez C, et al.
AIDS
. 2016 Feb;
30(8):1209-20.
PMID: 26854807
Background: The proportion of HIV controllers developing virologic, immunological or clinical progression and the baseline predictors of these outcomes have not been assessed in large cohorts. Methods: A multicenter cohort...